HemaCare Corporation (HEMA), profitable Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : HemaCare Corporation (HEMA), profitable

HEMA 25.31

+0.6%

Jan 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Trimble who wrote (60)	3/15/2000 2:42:00 PM
From: MeDroogies	of 70

With news like this...we should see some nice climbing in the near term. HemaCare Announces Pilot Program With Cypress Bioscience to Expand Treatments Utilizing the PROSORBA Column LOS ANGELES--(BW HealthWire)--March 13, 2000--HemaCare Corp. (OTCBB:HEMA) today announced a cooperative pilot program with Cypress Bioscience Inc. (Nasdaq:CYPB), to provide PROSORBA Column treatments in Rheumatologists' offices. The pilot program will include up to five sites in California and New York. The PROSORBA column was approved by the FDA for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) in 1979. In early 1999, it was approved for moderate to severe Rheumatoid Arthritis (RA) in adult patients with long-standing disease who have failed or are intolerant to anti-rheumatic drugs. PROSORBA Column procedures and other therapeutic apheresis services are currently performed primarily in a hospital setting. The objective of this pilot program is to provide better continuity of patient care by allowing the Rheumatologist to maintain supervision of the patient during the 12-week Prosorba protocol. A physician's office does not typically have the necessary personnel and equipment required to provide PROSORBA Column treatments. During this pilot program, HemaCare will provide all equipment and nursing. HemaCare will also provide education and training to participating physicians and their staff. Cypress will offer management support to assist the physician practice as part of a comprehensive service program. "HemaCare has had extensive experience with the PROSORBA column and has been administering PROSORBA Column treatments in the hospital for Idiopathic Thrombocytopenic Purpura (ITP) for several years," said Joshua Levy, M.D., Rheumatologist, and Medical Director of HemaCare. "We have also been providing PROSORBA Column treatment for Rheumatoid Arthritis (RA) since April of 1999. HemaCare is committed to expanding PROSORBA and therapeutic apheresis services nationally and this cooperative program is a significant step towards achieving that goal."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next